Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses

CSL Limited (OTC:CSLLY) and Arcturus Therapeutics (NASDAQ:ARCT) announced the results of a Phase 3 head-to-head study of ARCT-154, a self-amplifying (sa-mRNA) COVID-19 vaccine, compared to Pfizer Inc’s (NYSE:PFE) shot Comirnaty.

The study showed that the sa-mRNA COVID-19 vaccine maintained superior immunogenicity compared to the conventional mRNA vaccine Comirnaty for up to one year against Wuhan-Hu-1, Omicron BA.4-5 and certain other variants, and at one-sixth the dose of the comparator (5 μg vs. 30 μg, respectively).

Also Read: Arcturus’ Inhaled mRNA Therapeutic In Cystic Fibrosis Study Highlights Potential Amid Competitive Landscape: Analyst.

The COVID-19 vaccine from this sa-mRNA platform targeted against the JN.1 variant is approved in Japan for immunization against COVID-19 in adults 18 years and older. It is being sold under the trade name Kostaive.

At Day 29, neutralizing antibodies (GMTs unadjusted) against the Wuhan-Hu-1 strain in ARCT-154 recipients (n = 378) were superior to those in the Comirnaty group (n = 374)

GMT = 5390 vs. 3738, a GMT ratio of 1.44. This advantage persisted through all time points. At Day 361 (unadjusted), GMTs were 3396 and 1771 in ARCT-154 (n = 272) and Comirnaty (n = 266) groups, with a GMT ratio of 1.92. Differences were also observed in responses against Omicron BA.4-5, with GMT ratios of 1.31 at Day 29 and 1.89 at Day 361.

Additional data presented by CSL and Arcturus finds that the bivalent formula ARCT-2301, developed on the same platform as ARCT-154, induces superior immunogenicity over conventional bivalent mRNA vaccine Comirnaty, which persists against key variants up to six months postvaccination.

Data from 930 participants showed that ARCT-2301 (n = 398) induced superior neutralizing antibody responses vs. Comirnaty (n = 405) against Omicron BA.4-5 (GMT ratio 1·49), and against Wuhan-Hu-1 (GMT ratio 1.45). The difference persisted through six months with GMT ratios of 2.17 and 1.98, respectively. Antibody responses against Omicron XBB.1.5 were also higher after ARCT-2301 vs. Comirnaty.

Price Action: ARCT stock is up 4.70% at $23.07 at last check Monday.

Image via Unsplash

Read Next:

Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline.

Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.

Get the latest stock analysis from Benzinga?



PFIZER (PFE): Free Stock Analysis Report ARCTURUS THERAPEUTICS (ARCT): Free Stock Analysis Report

This article Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses originally appeared on Benzinga.com

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.